Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intratumoral IDOV-SAFE in Advanced Solid Tumors
NCT06713148Phase 1Not yet recruiting
- Sponsor
- Fudan University
- Start
- Apr 2025
- Primary completion
- Dec 2025
- Modality
- Oncolytic Viruses
01
Overview
Phase 1, open-label, single-arm trial of IDOV-Safe in solid tumor (advanced stage), sponsored by Fudan University. Primary endpoints: Dose Limiting Toxicities at 3 weeks and Incidence of Adverse Events at 2 years. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
IDOV-Safe
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06713148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06713148.